1,411 results on '"Llorca, F."'
Search Results
2. Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trial
3. Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023
4. Real-world EGFR testing practices for non-small-cell lung cancer by thoracic pathology laboratories across Europe
5. Retrospective study to estimate the prevalence and describe the clinicopathological characteristics, treatments received, and outcomes of HER2-low breast cancer
6. ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer
7. Potential histological discordance revealed by second review in the national rare gynecological cancer network (TMRG)
8. Le ganglion sentinelle : point de vue du pathologiste avec un focus sur l'expérience dans le cancer du sein
9. European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer
10. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
11. Refining patient selection for breast cancer immunotherapy: beyond PD-L1
12. Delayed care for patients with newly diagnosed cancer due to COVID-19 and estimated impact on cancer mortality in France
13. ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research
14. Clinical and molecular practice of European thoracic pathology laboratories during the COVID-19 pandemic. The past and the near future
15. Image-based multiplex immune profiling of cancer tissues: translational implications. A report of the International Immuno-oncology Biomarker Working Group on Breast Cancer
16. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
17. Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network
18. Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration
19. ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib
20. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
21. Elacestrant in ESR1-mutant, endocrine-responsive metastatic breast cancer: should health authorities consider post hoc data to inform priority access?
22. 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
23. Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer
24. Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer
25. A phase Ib dose allocation study of oral administration of lucitanib given in combination with fulvestrant in patients with estrogen receptor-positive and FGFR1-amplified or non-amplified metastatic breast cancer
26. Networking for ovarian rare tumors: a significant breakthrough improving disease management
27. 3rd ESO–ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3)
28. European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer
29. 20P Spatial analysis of residual tumor tissue provides new clues for post-neoadjuvant treatment approaches in triple-negative breast cancer
30. SA 8.1 Assessing HER2 heterogeneity
31. Pitfalls in machine learning-based assessment of tumor-infiltrating lymphocytes in breast cancer: a report of the international immuno-oncology biomarker working group
32. Spatial analyses of immune cell infiltration in cancer: current methods and future directions. A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer
33. Pitfalls in machine learning-based assessment of tumor-infiltrating lymphocytes in breast cancer: a report of the international immuno-oncology biomarker working group.
34. Spatial analyses of immune cell infiltration in cancer: current methods and future directions. A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer.
35. Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study
36. Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer
37. Facteurs pronostiques des carcinomes lobulaires infiltrants du sein : à propos de 940 cas
38. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
39. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)
40. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
41. Classification et signatures moléculaires des cancers du sein en 2017
42. Understanding the current use of breast cancer multigene signatures in clinical practice across Europe: global results from the PROCURE Project
43. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
44. Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact
45. Present and future breast cancer management—bench to bedside and back: a positioning paper of academia, regulatory authorities and pharmaceutical industry
46. Characteristics and clinical outcome of T1 breast cancer: a multicenter retrospective cohort study
47. Medical students faced with related and unrelated living kidney donation: a stratified and multicentre study in Spain
48. 164P Current use of breast cancer multigene signatures in clinical practice among European experts: Results from the PROCURE Project
49. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
50. Comparison of the prognostic value of genomic grade index, Ki67 expression and mitotic activity index in early node-positive breast cancer patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.